OCTAGAM 10% infusion rate chart for adult patients with chronic immune thrombocytopenic purpura (cITP)[1]

octagam® 10%
Immune Globulin
Intravenous (Human) 10%
Liquid Preparation

The OCTAGAM 10% infusion rate chart below will help you calculate the appropriate infusion rate for a patient with cITP

For patients with cITP: 2 g/kg divided in equal doses given over 2 consecutive days[1]

Patient Weight		Infusion Rate (mL/hr)				
In kg	In lb	First 30 minutes (0.01 mL/kg/min)	Next 30 minutes *(if tolerated)* (0.02 mL/kg/min)	Next 30 minutes *(if previous rate tolerated)* (0.04 mL/kg/min)	Next 30 minutes *(if previous rate tolerated)* (0.08 mL/kg/min)	Maximum *(if previous rate tolerated)* (<0.12 mL/kg/min)
40	88	24	48	96	192	≤288
45	99	27	54	108	216	≤324
50	110	30	60	120	240	≤360
55	121	33	66	132	264	≤396
60	132	36	72	144	288	≤432
65	143	39	78	156	312	≤468
70	154	42	84	168	336	≤504
75	165	45	90	180	360	≤540
80	176	48	96	192	384	≤576
85	187	51	102	204	408	≤612
90	198	54	108	216	432	≤648
95	209	57	114	228	456	≤684
100	220	60	120	240	480	≤720
105	231	63	126	252	504	≤756
110	242	66	132	264	528	≤792
115	253	69	138	276	552	≤828
120	264	72	144	288	576	≤864
125	275	75	150	300	600	≤900

For patients at risk for developing renal dysfunction or thromboembolic events, administer OCTAGAM 10% at the minimum infusion rate practicable, not to exceed 0.03 mL/kg/min (3.33 mg/kg/min)—equal to 2.0 mL/kg/hr (200 mg/kg/hr)[1]

INDICATIONS AND USAGE

OCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults.

Please click here for Full Prescribing Information, including BOXED WARNING.

octapharma

OCTAGAM 10% Indication and Usage and Important Safety Information

octagam® 10%

Immune Globulin
Intravenous (Human) 10%
Liquid Preparation

INDICATION AND USAGE

OCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE

- Thrombosis may occur with immune globulin intravenous (IgIV) products, including OCTAGAM 10% liquid. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
- Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IgIV products, including OCTAGAM 10% liquid. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IgIV products containing sucrose. OCTAGAM 10% liquid does not contain sucrose.
- For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer OCTAGAM 10% liquid at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Dosing and Administration

Patients with dermatomyositis are at increased risk for thromboembolic events; monitor carefully and do not exceed an infusion rate of 0.04 mL/kg/min.

Contraindications

OCTAGAM 10% liquid is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.

Warnings and Precautions

OCTAGAM 10% liquid may cause hypersensitivity in patients with a corn allergy. OCTAGAM 10% liquid contains maltose, which is derived from corn.
Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure.
Falsely elevated blood glucose readings may occur during and after the infusion of OCTAGAM 10% liquid with testing by some glucometers and test strip systems.
Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving OCTAGAM 10% liquid.
Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to treatment with OCTAGAM 10% liquid. Risk factors for hemolysis include high doses and non–O-blood group. Closely monitor patients for hemolysis and hemolytic anemia.
Aseptic meningitis syndrome may occur in patients receiving OCTAGAM 10% liquid, especially with high doses or rapid infusion.
Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]).
OCTAGAM 10% liquid is made from human plasma and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease agent.

Adverse Reactions

cITP - The most common adverse reactions reported in >5% of study subjects were headache, fever, and increased heart rate.
DM - The most common adverse reactions reported in >5% of study subjects were headache, fever, nausea, vomiting, increased blood pressure, chills, musculoskeletal pain, increased heart rate, dyspnea, and infusion site reactions.

Reference: 1. OCTAGAM 10% [prescribing information]. Paramus, NJ: Octapharma USA Inc.; 2021.

To report suspected adverse reactions, contact Octapharma USA, Inc. at 1-866-766-4860 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OCTAGAM® is a registered trademark of Octapharma AG.

Please click here for Full Prescribing Information, including BOXED WARNING.

octapharma

Manufactured by Octapharma Pharmazeutica Produktionsges m.b.H.
Distributed by Octapharma USA Inc.

Date of preparation: 03/2026 GAM10-0636